Literature DB >> 19741291

Antibiotic resistance among Salmonella enterica serovars Typhi and Paratyphi A in Pakistan (2001-2006).

Rumina Hasan1, Afia Zafar, Zohair Abbas, Vikram Mahraj, Faisal Malik, Anita Zaidi.   

Abstract

OBJECTIVES: To compare antimicrobial resistance in S. Typhi and S. Paratyphi A isolates from Pakistan.
METHODS: Blood samples were collected through > 175 laboratory collection points in major cities and towns across the country. The study included 3,671 S. Typhi and 1,475 S. Paratyphi A isolates (2001-2006). Multidrug resistance (MDR) was defined as resistance to first-line agents co-trimoxazole, chloramphenicol and ampicillin.
RESULTS: In total, 79.3% S. Typhi and 59.9% S. Paratyphi A were isolated from patients under 15 years of age. During the study period, the MDR rate increased in S. Typhi (34.2 to 48.5% p<0.001). Quinolone resistance (MIC> 1 microg/ml) increased in both S. Typhi (1.6 to 64.1% p<0.001) and S. Paratyphi A (0 to 47% p<0.001). The increase in the proportion of strains showing high level quinolone resistance (MIC > 4 microg/ml) was greater in S. Paratyphi A when compared to S. Typhi. Resistance to first-line drugs was higher in those <15 years of age whereas quinolone resistance was higher in older patients.
CONCLUSION: Differences between S. Typhi and S. Paratyphi A, in terms of evolution of resistance to first-line agents and to quinolones, are evident in this population. The rapid increase in quinolone resistance in S. Paratyphi A when compared to S. Typhi is concerning and requires further study.

Entities:  

Mesh:

Year:  2008        PMID: 19741291     DOI: 10.3855/jidc.224

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  12 in total

1.  Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.

Authors:  Imran Ahmed; Kauser Jabeen; Raunaq Inayat; Rumina Hasan
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

2.  The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy.

Authors:  Christopher M Parry; Ha Vinh; Nguyen Tran Chinh; John Wain; James I Campbell; Tran Tinh Hien; Jeremy J Farrar; Stephen Baker
Journal:  PLoS Negl Trop Dis       Date:  2011-06-21

3.  Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa.

Authors:  Robert F Breiman; Leonard Cosmas; Henry Njuguna; Allan Audi; Beatrice Olack; John B Ochieng; Newton Wamola; Godfrey M Bigogo; George Awiti; Collins W Tabu; Heather Burke; John Williamson; Joseph O Oundo; Eric D Mintz; Daniel R Feikin
Journal:  PLoS One       Date:  2012-01-19       Impact factor: 3.240

4.  Estimating the burden of paratyphoid a in Asia and Africa.

Authors:  Michael B Arndt; Emily M Mosites; Mu Tian; Mohammad H Forouzanfar; Ali H Mokhdad; Margaret Meller; Rion L Ochiai; Judd L Walson
Journal:  PLoS Negl Trop Dis       Date:  2014-06-05

5.  Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.

Authors:  Marina Antillón; Joke Bilcke; A David Paltiel; Virginia E Pitzer
Journal:  Vaccine       Date:  2017-05-17       Impact factor: 3.641

6.  Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study.

Authors:  Nathan C Lo; Ribhav Gupta; Jeffrey D Stanaway; Denise O Garrett; Isaac I Bogoch; Stephen P Luby; Jason R Andrews
Journal:  J Infect Dis       Date:  2018-11-10       Impact factor: 5.226

Review 7.  Typhoid fever: Control & challenges in India.

Authors:  Bratati Mukhopadhyay; Dipika Sur; Sanjukta Sen Gupta; N K Ganguly
Journal:  Indian J Med Res       Date:  2019-11       Impact factor: 2.375

8.  Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.

Authors:  Maria Rosario Capeding; Samuel Teshome; Tarun Saluja; Khalid Ali Syed; Deok Ryun Kim; Ju Yeon Park; Jae Seung Yang; Yang Hee Kim; Jiwook Park; Sue-Kyoung Jo; Yun Chon; Sudeep Kothari; Seon-Young Yang; Dong Soo Ham; Ji Hwa Ryu; Hee-Seong Hwang; Ju-Hwan Mun; Julia A Lynch; Jerome H Kim; Hun Kim; Jean-Louis Excler; Sushant Sahastrabuddhe
Journal:  Vaccine       Date:  2018-06-18       Impact factor: 3.641

9.  A Retrospective Review of Hospital-Based Data on Enteric Fever in India, 2014-2015.

Authors:  Dipika Sur; Caitlin Barkume; Bratati Mukhopadhyay; Kashmira Date; Nirmal Kumar Ganguly; Denise Garrett
Journal:  J Infect Dis       Date:  2018-11-10       Impact factor: 5.226

10.  Drug-resistant enteric fever worldwide, 1990 to 2018: a systematic review and meta-analysis.

Authors:  Annie J Browne; Bahar H Kashef Hamadani; Emmanuelle A P Kumaran; Puja Rao; Joshua Longbottom; Eli Harriss; Catrin E Moore; Susanna Dunachie; Buddha Basnyat; Stephen Baker; Alan D Lopez; Nicholas P J Day; Simon I Hay; Christiane Dolecek
Journal:  BMC Med       Date:  2020-01-03       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.